Outcomes of patients with chronic plaque psoriasis and hidradenitis suppurativa on biologic therapy during the Covid-19 pandemic: A UK dermatology tertiary centre experience.

Retrospective review data from 183 patients with psoriasis and/or hidradenitis suppurativa from a UK tertiary dermatology centre, suggests biologic therapy does not confer a significant increased risk of contracting severe Covid-19 in this cohort. This is in line with a growing body of evidence which indicates that it is safe to continue using biologic therapies during the pandemic.